Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

12. März 2019 07:00 ET | Quelle: Recro Pharma, Inc.

Recro Pharma to Host Educational Symposium on Pain Management Options in Total Joint Replacements at the American Academy of Orthopaedic Surgeons 2019 Annual Meeting

MALVERN, Pa., March 12, 2019 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for hospitals and other acute care...
04. März 2019 07:00 ET | Quelle: Recro Pharma, Inc.

Recro Pharma Obtains $40.5 Million of Non-Dilutive Capital Through Expanded Credit Facility

MALVERN, Pa., March 04, 2019 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for hospitals and other acute care...
25. Februar 2019 16:05 ET | Quelle: Recro Pharma, Inc.

Recro Pharma Announces Publication of Phase III IV Meloxicam Clinical Safety and Opioid Use Data in the Journal Clinical Pharmacology in Drug Development

MALVERN, Pa., Feb. 25, 2019 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for hospitals and other acute care...
20. Februar 2019 07:00 ET | Quelle: Recro Pharma, Inc.

Recro Pharma Announces New IV Meloxicam Data Publication in the Journal Regional Anesthesia & Pain Medicine

MALVERN, Pa., Feb. 20, 2019 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for hospitals and other acute care...
19. Februar 2019 07:00 ET | Quelle: Recro Pharma, Inc.

Recro Pharma Reports Financial Results for the Fourth Quarter and Year End 2018

March 24, 2019 PDUFA Goal Date for IV Meloxicam Record CDMO Performance; 2018 Revenues of $77.3 Million Company to Host Conference Call Today at 8:00 AM ET MALVERN, Pa., Feb. 19, 2019 (GLOBE...
14. Februar 2019 07:00 ET | Quelle: Recro Pharma, Inc.

Recro Pharma to Report Fourth Quarter and Year End 2018 Financial Results and Host Conference Call and Webcast on February 19, 2019

MALVERN, Pa., Feb. 14, 2019 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care...
11. Februar 2019 07:00 ET | Quelle: Recro Pharma, Inc.

Recro Pharma Announces Five-Year Manufacturing and Supply Agreement Between Novartis and Recro Gainesville

Company Continues Long-Term, Strategic Relationship with Key Customer Recro Gainesville to be Exclusive Supplier of Ritalin LA® and Focalin XR® Capsules with “Total Revenue Per Capsule Economics”...
02. Januar 2019 07:00 ET | Quelle: Recro Pharma, Inc.

Recro Pharma Amends Athyrium Credit Facility

New Terms Provide for Continued Access to $40 Million in Debt Funding $10 Million of the $40 Million Funded at Closing MALVERN, Pa., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Recro Pharma, Inc....
21. Dezember 2018 07:00 ET | Quelle: Recro Pharma, Inc.

Recro Pharma Amends IV Meloxicam License Agreement with Alkermes

MALVERN, Pa., Dec. 21, 2018 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care...
10. Dezember 2018 07:00 ET | Quelle: Recro Pharma, Inc.

Recro Pharma Announces Presentation of New Data Demonstrating IV Meloxicam’s Effect on Platelet Function at the 72nd PostGraduate Assembly in Anesthesiology

MALVERN, Pa., Dec. 10, 2018 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care...

Vorherige Seite

Nächste Seite